RT Journal Article
SR Electronic
T1 Differential Antibody Response To Polysaccharide Vaccines Following Allogeneic Stem Cell Transplantation; A Dynamical Systems Perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.01.24309800
DO 10.1101/2024.07.01.24309800
A1 Zelikson, Viktoriya
A1 Khan, Maheen
A1 Horton, Morgan
A1 Ho, Thuy
A1 Roberts, Catherine
A1 Toor, Amir
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.07.01.24309800.abstract
AB Bacterial polysaccharide vaccination is generally commenced within 6 months to 1 year following SCT. Antibody responses to these vaccines tend to be variable, raising concerns for inadequate protection from infection and the potential for repeated vaccination. This landmark analysis was performed to evaluate pathogen specific antibody titers, as well as helper T cell and B cell recovery from transplant and post-vaccination amongst patients surviving at least 6 months post allogeneic SCT. Antibody titers to various pneumococcal serotypes and Hemophilus influenza type B (HiB) followed a Power Law distribution in each individual at all time points evaluated. Distinct serotype vaccine responses were observed and antibody titer hierarchy developed early after vaccination and was maintained over time. When B cell recovery was modeled as a function of helper T cell reconstitution over time, the robustness of the antibody response was dependent on threshold values of cellular immune recovery. These suggest that antibody responses are a highly regulated dynamical system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Virginia Commonwealth University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors